as 11-12-2024 4:00pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Founded: | 2003 | Country: | United States |
Employees: | N/A | City: | AUSTIN |
Market Cap: | 15.3B | IPO Year: | 2015 |
Target Price: | $129.40 | AVG Volume (30 days): | 938.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.44 | EPS Growth: | N/A |
52 Week Low/High: | $49.97 - $140.00 | Next Earning Date: | 11-12-2024 |
Revenue: | $1,360,503,000 | Revenue Growth: | 46.13% |
Revenue Growth (this year): | 42.99% | Revenue Growth (next year): | 13.31% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Oct 28 '24 | Sell | $118.21 | 1,196 | $141,379.76 | 110,695 | |
RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Oct 28 '24 | Sell | $118.21 | 1,057 | $124,948.50 | 206,027 | |
Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Oct 28 '24 | Sell | $118.21 | 3,960 | $468,113.58 | 189,762 | |
Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Oct 24 '24 | Sell | $119.00 | 1,605 | $191,037.37 | 72,709 | |
Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Oct 22 '24 | Sell | $119.09 | 496 | $59,068.49 | 72,709 | |
Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Oct 21 '24 | Sell | $120.41 | 550 | $66,241.10 | 110,695 | |
RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Oct 20 '24 | Sell | $120.41 | 816 | $98,298.04 | 206,027 | |
Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Oct 20 '24 | Sell | $120.41 | 1,062 | $127,932.28 | 72,709 | |
Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Oct 20 '24 | Sell | $120.41 | 2,602 | $313,597.08 | 189,762 | |
Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Oct 15 '24 | Sell | $130.40 | 4,523 | $589,796.94 | 189,762 |
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Business Wire
18 hours ago
GuruFocus.com
2 days ago
Business Wire
5 days ago
Business Wire
12 days ago
Simply Wall St.
13 days ago
Simply Wall St.
14 days ago
Zacks
21 days ago
Business Wire
22 days ago
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.